Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.
2.

The clinical utility of long-term humidification therapy in chronic airway disease.

Rea H, McAuley S, Jayaram L, Garrett J, Hockey H, Storey L, O'Donnell G, Haru L, Payton M, O'Donnell K.

Respir Med. 2010 Apr;104(4):525-33. doi: 10.1016/j.rmed.2009.12.016. Epub 2010 Feb 9.

3.

Cost-effectiveness of telehealthcare to patients with chronic obstructive pulmonary disease: results from the Danish 'TeleCare North' cluster-randomised trial.

Witt Udsen F, Lilholt PH, Hejlesen O, Ehlers L.

BMJ Open. 2017 May 17;7(5):e014616. doi: 10.1136/bmjopen-2016-014616.

4.

Self-management support for moderate-to-severe chronic obstructive pulmonary disease: a pilot randomised controlled trial.

Taylor SJ, Sohanpal R, Bremner SA, Devine A, McDaid D, Fernández JL, Griffiths CJ, Eldridge S.

Br J Gen Pract. 2012 Oct;62(603):e687-95. doi: 10.3399/bjgp12X656829.

5.

Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.

Briggs AH, Lozano-Ortega G, Spencer S, Bale G, Spencer MD, Burge PS.

Value Health. 2006 Jul-Aug;9(4):227-35.

6.

Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.

Chiang CH.

Respirology. 2008 Sep;13(5):689-94. doi: 10.1111/j.1440-1843.2008.01308.x. Epub 2008 May 29.

PMID:
18513247
7.

Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial.

Henderson C, Knapp M, Fernández JL, Beecham J, Hirani SP, Cartwright M, Rixon L, Beynon M, Rogers A, Bower P, Doll H, Fitzpatrick R, Steventon A, Bardsley M, Hendy J, Newman SP; Whole System Demonstrator evaluation team.

BMJ. 2013 Mar 20;346:f1035. doi: 10.1136/bmj.f1035. Erratum in: BMJ. 2013;346:j2065.

8.

Cost-utility analysis of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy.

Jódar-Sánchez F, Ortega F, Parra C, Gómez-Suárez C, Bonachela P, Leal S, Pérez P, Jordán A, Barrot E.

J Telemed Telecare. 2014 Sep;20(6):307-16. doi: 10.1177/1357633X14544421. Epub 2014 Jul 22.

PMID:
25052387
9.

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

Oostenbrink JB, Rutten-van Mölken MP, Monz BU, FitzGerald JM.

Value Health. 2005 Jan-Feb;8(1):32-46.

10.

Cost-effectiveness of early assisted discharge for COPD exacerbations in The Netherlands.

Goossens LM, Utens CM, Smeenk FW, van Schayck OC, van Vliet M, van Litsenburg W, Braken MW, Rutten-van Mölken MP.

Value Health. 2013 Jun;16(4):517-28. doi: 10.1016/j.jval.2013.01.010. Epub 2013 May 3.

11.

Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.

Hettle R, Wouters H, Ayres J, Gani R, Kelly S, Lion M, Decramer M.

Respir Med. 2012 Dec;106(12):1722-33. doi: 10.1016/j.rmed.2012.09.006. Epub 2012 Oct 3.

12.

Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective?

Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Mölken MP.

Eur Respir J. 2010 Jan;35(1):79-87. doi: 10.1183/09031936.00043309. Epub 2009 Jul 2.

13.

Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.

Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA.

Int J Chron Obstruct Pulmon Dis. 2012;7:757-64. doi: 10.2147/COPD.S36997. Epub 2012 Nov 1.

14.

The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial.

Grant A, Wileman S, Ramsay C, Bojke L, Epstein D, Sculpher M, Macran S, Kilonzo M, Vale L, Francis J, Mowat A, Krukowski Z, Heading R, Thursz M, Russell I, Campbell M; REFLUX Trial Group.

Health Technol Assess. 2008 Sep;12(31):1-181, iii-iv.

15.
16.

Oxygen With Cold Bubble Humidification Is No Better Than Dry Oxygen in Preventing Mucus Dehydration, Decreased Mucociliary Clearance, and Decline in Pulmonary Function.

Franchini ML, Athanazio R, Amato-Lourenço LF, Carreirão-Neto W, Saldiva PH, Lorenzi-Filho G, Rubin BK, Nakagawa NK.

Chest. 2016 Aug;150(2):407-14. doi: 10.1016/j.chest.2016.03.035. Epub 2016 Apr 2.

PMID:
27048871
17.

Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.

Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, Al MJ, Feenstra TL.

Value Health. 2011 Dec;14(8):1039-47. doi: 10.1016/j.jval.2011.06.008. Epub 2011 Sep 22.

18.

Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios.

Hoogendoorn M, Feenstra TL, Asukai Y, Borg S, Hansen RN, Jansson SA, Samyshkin Y, Wacker M, Briggs AH, Lloyd A, Sullivan SD, Rutten-van Mölken MP.

Value Health. 2014 Jul;17(5):525-36. doi: 10.1016/j.jval.2014.03.1721. Epub 2014 May 14.

19.

[Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].

Jahnz-Różyk K, Targowski T, From S, Faluta T, Borowiec L.

Pneumonol Alergol Pol. 2011;79(5):337-42. Polish.

20.

Supplemental Content

Support Center